Chronic Myeloproliferative Disorders Treatment - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Chronic Myeloproliferative Disorders Treatment (PDQ®)

Patient Version

Health Professional Version

En español

Last Modified: 02/22/2008


General Information About Chronic Myeloproliferative Disorders


		Chronic Myelogenous Leukemia


Polycythemia Vera


Chronic Idiopathic Myelofibrosis


Essential Thrombocythemia


Chronic Neutrophilic Leukemia


Chronic Eosinophilic Leukemia


Stages of Chronic Myeloproliferative Disorders


Treatment Option Overview


Treatment Options for Chronic Myeloproliferative Disorders


Get More Information From NCI


Changes to This Summary (02/22/2008)


About PDQ

Page Options

Print This Page

Print This Document

View Entire Document

E-Mail This Document

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups NIH Calendar of Events Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	New Study of Targeted Therapies for Breast Cancer The Nation's Investment in Cancer Research FY 2009 President's Cancer Panel Annual Report: 2006-2007 Cancer Trends Progress Report: 2007 Update Past Highlights

Chronic Myelogenous Leukemia

Chronic myelogenous leukemia is a disease in which too many white blood cells are made in the bone marrow. See the PDQ summary on Chronic Myelogenous Leukemia Treatment for information on diagnosis, staging, and treatment.

< Previous Section | Next Section >

| | | | | | | |

A Service of the National Cancer Institute